首页> 外文期刊>Neurology: Official Journal of the American Academy of Neurology >Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
【24h】

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

机译:低对比度信捕捉视觉敏度测试多发性硬化患者的功能障碍。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC). METHODS: L-CLA testing was conducted in two MS patient cohorts. In the MSFC Validation Study, 137 participants from a Phase III trial of inteferon beta-1a (Avonex) for relapsing-remitting MS were followed. A second cohort included 65 patients with secondary progressive MS who participated in a substudy of the International MS Secondary Progressive Avonex Controlled Trial (IMPACT). The total number of letters read correctly at four contrast levels (100, 5, 1.25, and 0.6%) was correlated with Expanded Disability Status Scale (EDSS), MSFC, Sickness Impact Profile, Multiple Sclerosis Quality of Life Inventory, and brain parenchymal fraction (BPF), as determined by MRI. RESULTS: Low- and high-contrast letter acuity scores correlated with BPF at follow-up in the MSFC Validation Study (5%: r = 0.40, p < 0.0001; 100%: r = 0.31, p = 0.0002). L-CLA also correlated with EDSS (5%: r = -0.35, p < 0.0001; 1.25%: r = -0.26, p = 0.0003) and MSFC (5%: r = 0.47, p < 0.0001; 1.25%: r = 0.45, p < 0.0001). In the IMPACT Substudy, change in L-CLA scores from baseline to year 1 predicted subsequent change in the EDSS from year 1 to 2 at the 5% (p = 0.0142) and the 1.25% (p = 0.0038) contrast levels, after adjusting for change in MSFC scores from baseline to year 1. CONCLUSIONS: Low-contrast letter acuity (L-CLA) scores demonstrate concurrent and predictive validity in patients with relapsing-remitting and secondary progressive multiple sclerosis (MS). L-CLA testing provides additional information relevant to the MS disease process that is not entirely captured by the Multiple Sclerosis Functional Composite.
机译:摘要目的:探讨并发和预测低对比度的信敏度的有效性(L-CLA)测试的候选人可视化组件多发性硬化功能复合(所有)。方法:L-CLA测试是在两个女士进行的病人军团。从第三期临床试验的137名参与者inteferon beta-1a (Avonex)复发缓和多发性随访。组包括65名患者次要的进步的参与substudy的女士国际二级进步Avonex女士对照试验(影响)。字母在四个对比读正确的水平(100 5, 1.25, 0.6%)是相关的扩大残疾状态量表(eds),所有,疾病影响形象,多发性硬化症生活质量的库存,和脑实质分数(带通滤波器),由核磁共振。低收入和高对比度的信敏度分数在所有与带通滤波器在随访验证研究(5%:r = 0.40, p < 0.0001;r = 0.31, p = 0.0002)。eds (5%: r = -0.35, p < 0.0001;-0.26, p = 0.0003)和所有(5%:r = 0.47, p <0.0001;影响Substudy L-CLA分数的变化基线第一年预测随后的变化eds从1到2的5% (p = 0.0142)和1.25% (p = 0.0038)相比的水平,从基线调整变化的所有成绩年1。敏度(L-CLA)并发和成绩证明患者的预测效度复发缓和和次要进步多发性硬化(MS)。MS疾病相关的额外信息没有完全被的过程多发性硬化功能复合材料。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号